Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat

Linerixibat treatment leads to rapid, dose-dependent TSBA reductions. Baseline TSBA levels do not correlate with on-treatment pruritus change, suggesting they do not predict linerixibat response. Change in TSBA AUC_0-24 correlates significantly with, and can be predictive of, pruritus improvement in patients with PBC.